Idorsia H1 FY26 net loss widens to CHF 153 million; net sales climb 62% to CHF 91 million

• Idorsia posted a US GAAP net loss of CHF 153 million in H1 2026, swinging from net income in the prior-year period.
• US GAAP operating loss widened to CHF 63 million as net revenue fell to CHF 110 million.
• QUVIVIQ net sales climbed 62% year-on-year to CHF 91 million; full-year 2026 net sales guidance reaffirmed at CHF 200 million.
• Roland Wandeler will become CEO on Oct. 1; Jean-Paul Clozel said the group is focused on four growth drivers led by QUVIVIQ expansion.
• Non-GAAP operating loss widened to CHF 54 million, while non-GAAP operating expenses rose to CHF 160 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.